1.13
+1.80%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sonoma Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Sonoma Pharmaceuticals is based in Boulder, Colorado and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SNOA. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 March 2026, it reported revenue of $19.5m and a net loss of $3.2m. At that date it held total assets of $14.0m and shareholders' equity of $3.1m.
Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A.
In March 2026, we announced the U.S. retail launch of our advanced HOCl-based burn relief hydrogel in CVS and Walmart stores in the United States.
Also in March 2026, we announced the launch of Aquanil® AD, a hypochlorous acid based dermatology product line for sensitive skin, developed exclusively for Persōn & Covey, Inc. for distribution through its established over-the-counter dermatology channels in the United States.
In October 2025, we announced the registration of our manufacturing facility and listing of our Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
In October 2025, we announced the launch of a new HOCl wound cleanser for Medline Industries, LP, to be distributed into hospital systems, home healthcare and other healthcare channels across the United States.
In August 2025, Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel earned the National Psoriasis Foundation (NPF) Seal of Recognition, and in November 2025, Reliefacyn earned the National Rosacea Society (NRS) Seal of Acceptance.
Quoted from its 10-K, filed 16 Jun 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Jan 2007
- Employees
- 8
- Website
- sonomapharma.com ↗
- Head office
- 5445 CONESTOGA COURT, SUITE 150, BOULDER, CO, 80301
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Amy TromblyChief Executive Officer, Director, since 2019$597,076
- Mr. Jerry DvonchChief Financial Officer$357,527
- Mr. Bruce ThorntonChief Operating Officer, Executive Vice President, Corporate Secretary$532,369
- Mr. Jerry MclaughlinLead Independent Director$82,088
- Dr. Jay BirnbaumIndependent Director$72,088
- Mr. Philippe WeigerstorferIndependent Director$64,588
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 8 full-time employees
- Headquartered in Boulder, Colorado
- Offers multiple HOCl-based products for various health care applications
Weaknesses
- Limited employee count may restrict operational capacity
- IPO occurred in 2007, potentially indicating limited recent market activity
- Products are primarily focused on niche health care segments
Opportunities
- Expanding HOCl-based product applications in wound care and dermatology
- Growing demand for non-antibiotic wound care solutions
- Potential for increased market penetration in animal health care segment
Threats
- Competition from established pharmaceutical companies
- Dependence on a narrow product portfolio for revenue
- Regulatory challenges in the pharmaceutical industry
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.